Research Study

A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Principal Investigator 
Martin Gleave

Overview

Body Locations and Systems 
Prostate Cancer
Disorders and Conditions 
Cancers
ClinicalTrials.gov# 
NCT02257736
Status 
Closed to Recruitment
Study Start/End 
May 1, 2015 to Aug 31, 2021
Locations 
Diamond Health Care Centre
Name/Title 
Maureen Palmer, Research Coordinator
Phone 
604-875-5675
Email Address 
maureen.palmer@vch.ca
Purpose of Study 

The purpose of this study is to compare the radiographic progression-free survival (rPFS) of JNJ56021927 in combination with abiraterone acetate (AA) plus prednisone or prednisolone (AAP) and AAP in participants with chemotherapy-naive (participants who did not receive any chemotherapy [treatment of cancer using drugs]) metastatic castration-resistant prostate cancer (mCRPC) (cancer of prostate gland [gland that makes fluid that aids movement of sperm]).

Eligibility 

Visit ClinicalTrials.gov for more information. 

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.